Advertisement

News

Stay informed with the latest medical news impacting you and your patients.
Showing 721 - 740 of 80,143 results

Off-label dermatologic uses of IL-23 inhibitors.

While IL-23 inhibitors, which include guselkumab, tildrakizumab, and risankizumab, are currently FDA-approved solely for the treatment of psoriasis, several other inflammatory skin condition...

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

Advertisement